News
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...
Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...
Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, ...
Zepbound, a weight loss drug by Eli Lily, received FDA approval. How the tirzepatide-containing drug works, potential side effects, and insurance coverage.
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
Novo Nordisk's weight-loss medication, Wegovy, uses semaglutide, which only focuses on GLP-1. That difference translated to greater weight loss with Zepbound than Wegovy, a recent study found.
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results